Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Theravance Biopharma (TBPH) Other Gross PP&E Adjustments (2016 - 2025)

Theravance Biopharma has reported Other Gross PP&E Adjustments over the past 13 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 215.75% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, up 215.75% year-over-year, with the annual reading at $2.2 million for FY2025, 215.75% up from the prior year.
  • Other Gross PP&E Adjustments was $2.2 million for Q4 2025 at Theravance Biopharma, up from -$25.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $12.5 million in Q4 2021 and troughed at -$42.5 million in Q1 2021.
  • The 5-year median for Other Gross PP&E Adjustments is -$33.6 million (2024), against an average of -$26.6 million.
  • Year-over-year, Other Gross PP&E Adjustments tumbled 3259.58% in 2023 and then skyrocketed 215.75% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $12.5 million in 2021, then tumbled by 97.7% to $287000.0 in 2022, then tumbled by 3259.58% to -$9.1 million in 2023, then surged by 78.64% to -$1.9 million in 2024, then skyrocketed by 215.75% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Gross PP&E Adjustments are $2.2 million (Q4 2025), -$25.4 million (Q3 2025), and -$26.5 million (Q2 2025).